Moleculin Biotech's Annamycin Shows Strong Potential in AML Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2026
0mins
Source: Newsfilter
- High Prescribing Likelihood: Oncologists reported an average likelihood-to-prescribe score of 6 out of 7 for Annamycin, indicating strong enthusiasm for its potential in treating acute myeloid leukemia (AML), particularly for deep remissions and bridging to transplants.
- Significant Unmet Need: Despite advancements in targeted therapies, the survey revealed that R/R AML patients face substantial treatment gaps, especially those without actionable mutations, suggesting Annamycin's broad applicability could address this unmet need.
- Notable Safety Advantage: Physicians highlighted Annamycin's reduced cardiotoxicity as a critical differentiator, enabling the possibility of repeat dosing, which is particularly relevant for pediatric AML patients concerned about long-term survivorship due to traditional anthracycline limitations.
- Strong Payer Support: Insights from hospital administrators and insurers indicate that Annamycin's efficacy and safety profile are recognized, suggesting it could provide a compelling value proposition for a broad patient population, thereby enhancing its market acceptance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MBRX
Wall Street analysts forecast MBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.800
Low
20.00
Averages
24.33
High
31.00
Current: 2.800
Low
20.00
Averages
24.33
High
31.00
About MBRX
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moleculin Biotech's Annamycin Shows Strong Potential in AML Treatment
- High Prescribing Likelihood: Oncologists reported an average likelihood-to-prescribe score of 6 out of 7 for Annamycin, indicating strong enthusiasm for its potential in treating acute myeloid leukemia (AML), particularly for deep remissions and bridging to transplants.
- Significant Unmet Need: Despite advancements in targeted therapies, the survey revealed that R/R AML patients face substantial treatment gaps, especially those without actionable mutations, suggesting Annamycin's broad applicability could address this unmet need.
- Notable Safety Advantage: Physicians highlighted Annamycin's reduced cardiotoxicity as a critical differentiator, enabling the possibility of repeat dosing, which is particularly relevant for pediatric AML patients concerned about long-term survivorship due to traditional anthracycline limitations.
- Strong Payer Support: Insights from hospital administrators and insurers indicate that Annamycin's efficacy and safety profile are recognized, suggesting it could provide a compelling value proposition for a broad patient population, thereby enhancing its market acceptance.
See More
Moleculin Biotech Advances in AML Trial
- Clinical Trial Progress: Moleculin Biotech announced the enrollment of the 45th subject in its pivotal Phase 2B/3 MIRACLE trial, marking the final preparation phase for interim data unblinding expected in mid-2026, which could represent a significant inflection point for the company.
- Drug Development Outlook: Annamycin, the company's lead program, aims to treat relapsed or refractory acute myeloid leukemia (R/R AML) and is designed to avoid multidrug resistance mechanisms while reducing cardiotoxicity, indicating strong clinical potential.
- FDA Support: Following a successful Phase 1B/2 study, Moleculin believes it has substantially de-risked the development pathway towards potential approval for Annamycin, with future filings contingent on FDA feedback.
- Diverse Product Pipeline: In addition to Annamycin, Moleculin is developing drugs like WP1066 and WP1122 targeting brain tumors, pancreatic cancer, and pathogenic viruses, showcasing the company's broad focus in oncology and virology.
See More
Moleculin Biotech Advances Cardiac Safety Profile in Annamycin Trials
- Cardiac Safety Data: At the 2026 ASCO Annual Meeting, Moleculin Biotech presented data showing that Annamycin, administered at a median cumulative dose of 660 mg/m² to 90 patients with acute myeloid leukemia, demonstrated no detectable cardiotoxicity, indicating a potential best-in-class safety profile.
- Clinical Trial Support: The independent review conducted by Cleveland Clinic cardiology specialists further validated Annamycin's safety at high doses, suggesting a shift in traditional treatment limitations and enhancing its application prospects in oncology.
- Efficacy Data Highlights: In a Phase 1b/2 study evaluating Annamycin in combination with cytarabine, the drug exhibited a 50% complete remission rate and a 60% composite remission rate, underscoring its effectiveness in treating relapsed or refractory acute myeloid leukemia.
- Future Research Directions: Moleculin's ongoing pivotal Phase 2b/3 MIRACLE trial will further assess the combination of Annamycin and cytarabine, with unblinding expected in June 2026; positive results could establish a strong foundation for market introduction.
See More
Moleculin Biotech Presents Annamycin Cardiac Safety Data at ASCO Annual Meeting
- Cardiac Safety Data Presentation: Moleculin Biotech announced that pooled cardiac safety data for its lead drug candidate Annamycin will be presented at the 2026 ASCO Annual Meeting, highlighting its potential advantages in patients with acute myeloid leukemia and soft tissue sarcoma.
- Clinical Trial Results: An independent cardiac safety review of 90 patients treated with L-Annamycin revealed a median cumulative dose of 660 mg/m2, with no significant change in left ventricular ejection fraction, indicating a superior cardiac safety profile compared to traditional chemotherapy agents.
- Efficacy Support: Annamycin demonstrated a 50% complete remission rate and a median overall survival of 12.39 months in previous Phase 1b/2 studies, further supporting its potential as an effective chemotherapy option, particularly with its advantages in avoiding cardiotoxicity.
- Future Development Prospects: The acceptance of these findings underscores Annamycin's safety profile, enhancing its application prospects in the MIRACLE trial, which may provide new treatment options for AML patients and drive the company's strategic growth in oncology.
See More
Moleculin Biotech Reports Q1 Earnings Miss
- Earnings Miss: Moleculin Biotech reported a Q1 GAAP EPS of -$3.54, missing expectations by $2.08, indicating significant challenges in profitability that could impact investor confidence.
- Cash Position: As of March 31, 2026, the company had approximately $10.3 million in cash and cash equivalents, with management believing that current resources and recent financing will support operations into Q3 2026, reflecting a degree of financial stability.
- Financing Progress: Moleculin Biotech secured $8.3 million from warrant exercises and issued new five-year warrants, which not only bolstered liquidity but also provided funding for future R&D and operations.
- Market Reaction: Despite the poor financial performance, Moleculin Biotech has opportunities to improve its financial situation in the coming months through financing and cash management measures, warranting close attention from investors regarding future developments.
See More
Moleculin Biotech Reports Early Results from MIRACLE Trial Indicating 40% Remission Rate
- Clinical Trial Progress: Moleculin has enrolled 45 patients in the MIRACLE trial, with preliminary results indicating a 40% composite complete remission rate, suggesting Annamycin's potential to significantly improve outcomes for patients with difficult-to-treat acute myeloid leukemia (AML).
- Financing Enhances Operational Capacity: The company completed financing transactions in Q1 2026, generating approximately $8.3 million, which strengthens its near-term operational runway and is expected to support planned operations into Q3 2026.
- Global Intellectual Property Strategy: Moleculin has bolstered its global intellectual property strategy for Annamycin, now covering four continents, aiming to provide legal protection for its products in international markets and enhance its competitive position.
- Future Milestones: The first data unblinding for the MIRACLE trial is expected in Q2 2026, with plans to recruit 90 subjects thereafter, marking a critical advancement in the company's efforts in AML treatment and potentially paving the way for future drug applications.
See More
Moleculin Biotech's Annamycin Shows Strong Potential in AML Treatment
- High Prescribing Likelihood: Oncologists reported an average likelihood-to-prescribe score of 6 out of 7 for Annamycin, indicating strong enthusiasm for its potential in treating acute myeloid leukemia (AML), particularly for deep remissions and bridging to transplants.
- Significant Unmet Need: Despite advancements in targeted therapies, the survey revealed that R/R AML patients face substantial treatment gaps, especially those without actionable mutations, suggesting Annamycin's broad applicability could address this unmet need.
- Notable Safety Advantage: Physicians highlighted Annamycin's reduced cardiotoxicity as a critical differentiator, enabling the possibility of repeat dosing, which is particularly relevant for pediatric AML patients concerned about long-term survivorship due to traditional anthracycline limitations.
- Strong Payer Support: Insights from hospital administrators and insurers indicate that Annamycin's efficacy and safety profile are recognized, suggesting it could provide a compelling value proposition for a broad patient population, thereby enhancing its market acceptance.
See More
Moleculin Biotech Advances in AML Trial
- Clinical Trial Progress: Moleculin Biotech announced the enrollment of the 45th subject in its pivotal Phase 2B/3 MIRACLE trial, marking the final preparation phase for interim data unblinding expected in mid-2026, which could represent a significant inflection point for the company.
- Drug Development Outlook: Annamycin, the company's lead program, aims to treat relapsed or refractory acute myeloid leukemia (R/R AML) and is designed to avoid multidrug resistance mechanisms while reducing cardiotoxicity, indicating strong clinical potential.
- FDA Support: Following a successful Phase 1B/2 study, Moleculin believes it has substantially de-risked the development pathway towards potential approval for Annamycin, with future filings contingent on FDA feedback.
- Diverse Product Pipeline: In addition to Annamycin, Moleculin is developing drugs like WP1066 and WP1122 targeting brain tumors, pancreatic cancer, and pathogenic viruses, showcasing the company's broad focus in oncology and virology.
See More
Moleculin Biotech Advances Cardiac Safety Profile in Annamycin Trials
- Cardiac Safety Data: At the 2026 ASCO Annual Meeting, Moleculin Biotech presented data showing that Annamycin, administered at a median cumulative dose of 660 mg/m² to 90 patients with acute myeloid leukemia, demonstrated no detectable cardiotoxicity, indicating a potential best-in-class safety profile.
- Clinical Trial Support: The independent review conducted by Cleveland Clinic cardiology specialists further validated Annamycin's safety at high doses, suggesting a shift in traditional treatment limitations and enhancing its application prospects in oncology.
- Efficacy Data Highlights: In a Phase 1b/2 study evaluating Annamycin in combination with cytarabine, the drug exhibited a 50% complete remission rate and a 60% composite remission rate, underscoring its effectiveness in treating relapsed or refractory acute myeloid leukemia.
- Future Research Directions: Moleculin's ongoing pivotal Phase 2b/3 MIRACLE trial will further assess the combination of Annamycin and cytarabine, with unblinding expected in June 2026; positive results could establish a strong foundation for market introduction.
See More
Moleculin Biotech Presents Annamycin Cardiac Safety Data at ASCO Annual Meeting
- Cardiac Safety Data Presentation: Moleculin Biotech announced that pooled cardiac safety data for its lead drug candidate Annamycin will be presented at the 2026 ASCO Annual Meeting, highlighting its potential advantages in patients with acute myeloid leukemia and soft tissue sarcoma.
- Clinical Trial Results: An independent cardiac safety review of 90 patients treated with L-Annamycin revealed a median cumulative dose of 660 mg/m2, with no significant change in left ventricular ejection fraction, indicating a superior cardiac safety profile compared to traditional chemotherapy agents.
- Efficacy Support: Annamycin demonstrated a 50% complete remission rate and a median overall survival of 12.39 months in previous Phase 1b/2 studies, further supporting its potential as an effective chemotherapy option, particularly with its advantages in avoiding cardiotoxicity.
- Future Development Prospects: The acceptance of these findings underscores Annamycin's safety profile, enhancing its application prospects in the MIRACLE trial, which may provide new treatment options for AML patients and drive the company's strategic growth in oncology.
See More
Moleculin Biotech Reports Q1 Earnings Miss
- Earnings Miss: Moleculin Biotech reported a Q1 GAAP EPS of -$3.54, missing expectations by $2.08, indicating significant challenges in profitability that could impact investor confidence.
- Cash Position: As of March 31, 2026, the company had approximately $10.3 million in cash and cash equivalents, with management believing that current resources and recent financing will support operations into Q3 2026, reflecting a degree of financial stability.
- Financing Progress: Moleculin Biotech secured $8.3 million from warrant exercises and issued new five-year warrants, which not only bolstered liquidity but also provided funding for future R&D and operations.
- Market Reaction: Despite the poor financial performance, Moleculin Biotech has opportunities to improve its financial situation in the coming months through financing and cash management measures, warranting close attention from investors regarding future developments.
See More
Moleculin Biotech Reports Early Results from MIRACLE Trial Indicating 40% Remission Rate
- Clinical Trial Progress: Moleculin has enrolled 45 patients in the MIRACLE trial, with preliminary results indicating a 40% composite complete remission rate, suggesting Annamycin's potential to significantly improve outcomes for patients with difficult-to-treat acute myeloid leukemia (AML).
- Financing Enhances Operational Capacity: The company completed financing transactions in Q1 2026, generating approximately $8.3 million, which strengthens its near-term operational runway and is expected to support planned operations into Q3 2026.
- Global Intellectual Property Strategy: Moleculin has bolstered its global intellectual property strategy for Annamycin, now covering four continents, aiming to provide legal protection for its products in international markets and enhance its competitive position.
- Future Milestones: The first data unblinding for the MIRACLE trial is expected in Q2 2026, with plans to recruit 90 subjects thereafter, marking a critical advancement in the company's efforts in AML treatment and potentially paving the way for future drug applications.
See More
